Back to mobile site

Form 4 Nuo Therapeutics, Inc. For: May 29 Filed by: Pittman Scott M.

June 2, 2026 9:55 PM EDT
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Pittman Scott M.
(Last) (First) (Middle)
C/O NUO THERAPEUTICS, INC.
8285 EL RIO, SUITE190
(Street)
HOUSTON TX 77054
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Interim Warrant (right to buy) (1) $ 1.5 05/29/2026 (2)   A   17,450   05/29/2026 01/23/2031 Common Stock 17,450 $ 1.5 17,450 D  
Second Warrant (right to buy) (3) $ 1.5 05/29/2026 (2)   D (4)     36,750 09/30/2026 01/23/2031 Common Stock 36,750 $ 1.5 0 D  
Prepayment Warrant (right to buy) $ 1.5 05/29/2026 (2)   D (5)     7,516 01/23/2026 01/23/2031 Common Stock 7,516 $ 1.5 0 D  
Second Restated Warrant (right to buy) $ 1.5 05/29/2026 (2)   A (4)   17,500   09/30/2026 (6) 01/23/2031 Common Stock 17,500 $ 1.5 0 D  
Prepayment Restated Warrant (right to buy) $ 1.5 05/29/2026 (2)   A (5)   7,333 (7)   05/29/2026 (8) 01/23/2031 Common Stock 7,333 $ 1.5 0 D  
Explanation of Responses:
1. Represents Origination Interim and Capital Interim Warrants.
2. Transaction approved by Board of Directors of Issuer and Non-Employee Directors
3. Represents Origination Restated Second and Capital Restated Second Warrants.
4. Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").
5. Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement.
6. Vesting (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan Agreement.
7. Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.
8. Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.
/s/ David Jorden, attorney-in-fact 06/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. USO
2. SPY
3. QTTB
4. ERAS
5. PSKY
6. BIIB
7. AAPL
8. JPM
9. MU
10. SPCX


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings